Salix Pharma (SLXP) Reports Q4 EPS of $2.61

Salix Pharma (NASDAQ: SLXP) reported Q4 EPS of $2.61, may not compare to the analyst estimate of ($0.29). Revenue for the quarter came in at $13 million versus the consensus estimate of $187.97 million.

For earnings history and earnings-related data on Salix Pharma (SLXP) click here.

You May Also Be Interested In

• North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
• EquipmentShare.com Inc. (EQPT) Reports Q2 EPS of $0.18; Offers Guidance
• Pan American Silver (PAAS) Misses Q2 EPS by 19c